Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.47 |
| ▸ | CNR1 | P21554 | 5/20 | 0.47 |
| ▸ | TYK2 | P29597 | 6/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929052 | 1.00 | CNR2 (0.47) | CNR2CNR1TYK2KDM1AMAOB | |
| SCHEMBL8299116 | 0.84 | CNR2 (0.48) | CNR2CNR1TYK2RAB9AL3MBTL1 | |
| SCHEMBL6012264 | 0.84 | CNR2 (0.60) | CNR2CNR1TYK2RAB9A | |
| Hydrochloric Acid SCHEMBL4185132 | 0.83 | CNR2 (0.47) | CNR2CNR1TYK2RAB9AL3MBTL1 | |
| SCHEMBL4186958 | 0.83 | CACNB4 (0.42) | BTK | |
| SCHEMBL13929049 | 0.83 | CACNB4 (0.42) | BTK | |
| SCHEMBL8303269 | 0.83 | TYK2 (0.43) | CNR2TYK2KDM1AMAOBBTK | |
| SCHEMBL4198559 | 0.83 | TYK2 (0.43) | CNR2TYK2KDM1AMAOBBTK | |
| SCHEMBL13697676 | 0.83 | BTK (0.49) | CNR2CNR1KDM1AMAOBRAB9A | |
| SCHEMBL4100387 | 0.83 | BTK (0.49) | CNR2CNR1KDM1AMAOBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| US-20080194635-A1 | Crystalline Forms of Cis-5-Fluoro-N-[4-(2-Hydroxy-4-Methylbenzamido) Cyclohexyl]-2-(Tetrahydrothiopyran-4-Yloxy) Nicotinamide | PFIZER INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1651641-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | BARBER CHRISTOPHER G | 2006-08-10 | — | — | US | disclosed |
| EP-1683795-A1 | Crystalline forms of cis-5-fluoro-N-¬4-(2-hydroxy-4-methylbenzamido)cyclohexyl|-2-(tetrahydrothiopyran-4-yloxy)nicotinamide | Pfizer Limited (GB) | 2006-07-26 | — | — | EP | disclosed |
| US-20050043326-A1 | Compounds | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-20050020611-A1 | Compounds | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020611-A1 | Compounds | NQO1, NAMPT, NNT | CNR2 571/4885CNR1 529/4885TYK2 3691/4885 |
| US-20080194635-A1 | Crystalline Forms of Cis-5-Fluoro-N-[4-(2-Hydroxy-4-Methylbenzamido) Cyclohexyl]-2-(Tetrahydrothiopyran-4-Yloxy) Nicotinamide | SIRT5, NAMPT, SIRT4 | CNR2 2302/4885CNR1 3283/4885TYK2 3295/4885 |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | PDE4A, PDE4B, PDE4C | CNR2 1750/4885CNR1 1800/4885TYK2 4041/4885 |
| US-20090035313-A1 | Compounds | NQO1, NAMPT, NNT | CNR2 571/4885CNR1 529/4885TYK2 3691/4885 |
| US-20050043326-A1 | Compounds | NQO1, NAMPT, NNT | CNR2 571/4885CNR1 529/4885TYK2 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.